SWOG clinical trial number
S1316

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction

Closed
Phase
Accrual
100%
Abbreviated Title
Surgery vs Non-Surgical Management for MBO
Status Notes
Re-Activation - Effective 6/1/18
Activated
03/09/2015
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Cancer Survivorship
Gastrointestinal Cancer

Treatment

Surgery Non-surgical management

Other Study Materials

Eligibility Criteria Expand/Collapse

Must have malignant bowel obstruction (MBO); must have MBO due to an intra-abdominal primary cancer; must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems; a member of the surgical team must indicate equipoise for the benefit of the surgical treatment for MBO; pts must not have signs of bowel perforation or "acute" abdomen as evidenced by free air on radiologic imaging or peritonitis on a physical exam within 2 days prior to reg; must be registered within 3 days after surgical consult for MBO and prior to any treatment for MBO; Zubrod PS 0-2 within 7 days prior to reg; must plan to collect serum albumin after admission, but prior to treatment; must be able to complete study questionnaires in English; must be >/= 18 years old.

Publication Information Expand/Collapse

2025

Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial

C Thomson;K Arnold;G Anderson;V Sun;A Secord;A Yung;M Al-Kaspooles;V Nfonsam;M Grant;G Deutsch;J Deneve;R Krouse Journal of the Academy of Nutrition and Dietetics May;125(5):654-665.e3

PMid: PMID39603592 | PMC number: PMCIDPMC12009688

Lessons Learned from SWOG S1316: Optimizing Surgical Trial Design for Malignant Bowel Obstruction

M Farooq;N Amini;G Anderson;V Sun;G Deutsch;J Deneve;M Grant;R Krouse Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)

Secondary analysis of SWOG S1316 shows improved survival with surgical intervention for malignant bowel obstruction

J Lee;R Krouse Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)

Presence of Ascites in the Setting of Malignant Bowel Obstruction Leads to Shorter Survival

K Dougherty;J Lee;J Deneve Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)

Patient-reported outcomes (PROs) in the pragmatic comparative effectiveness trial of surgical versus non-surgical management for patients with malignant bowel obstruction (S1316)

A Dueck;K Arnold;G Anderson;C Thomson;A Secord;G Deutsch;J Deneve;R Krouse ISOQOL Meeting (22-25 October 2025 Milwaukee, WI)

2024

Evaluation of a prognostic scoring system among patients in the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction Study (SWOG 1316)

C Watson;K Arnold;R Krouse;G Anderson;J Deneve;G Deutsch;B Davidson;A Secord IGCS Meeting (October 16-18, 2024 Dublin, Ire), poster

2023

Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial

R Krouse;G Anderson;K Arnold;C Thomson;V Nfonsam;M Al-Kasspooles;J Walker;V Sun;A Alvarez Secord;E Han;A Leon-Takahashi;D Isla Ortiz;P Rodgers;S Hendren;M Sanchez Salcedo;J Laryea;W Graybill;D Flaherty;H Mogal;T Miner;J Pimiento;M Kitano;B Badgwell;G Whalen;J Lamont;O Guevara;M Senthil;S Dewdney;E Silberfein;J Wright;B Friday;B Fahy;S Anantha;M O'Rourke;M Bakitas;J Sloan;M Grant;G Deutsch;J Deneve Lancet Gastroenterology and Hepatology Aug 1;S2468-1253(23)00191-7

PMid: PMID37541263 | PMC number: PMC10530384

Ability to Eat among Cancer Patients Treated for Malignant Bowel Obstruction: A Secondary Analysis within SWOG S1316

C Thomson;G Anderson;K Arnold;V Sun;R Krouse ASPO Annual Meeting (March 12-14, 2023, San Diego, CA)

2020

Intellectual Equipoise and Challenges: Accruing Patients with Advanced Cancer to a Trial Randomizing to Surgical or Non-Surgical Management (SWOG S1316)

G Deutsch;J Deneve;M Al-Kasspooles;V Nfonsam;C Gunderson;A Alvarez Secord;P Rodgers;S Hendren;E Silberfein;ML Grant;J Sloan;V Sun;K Arnold;G Anderson;R Krouse American Journal of Hospice & Palliative Medicine Jan;37(1):12-18; May 23, 2019 [Epub ahead of print]

PMid: PMID31122027 | PMC number: PMC6868288

Sociocultural Factors of Cancer Clinical Trial Recruitment and Multidisciplinary Team Recruitment of Latin-American Patients in Mexico, Peru and Colombia

D Isla;R Krouse;A Mohar;A Leon;M Sanchez;O Guevara;M Lopez;LG Mora;N Macavilca;IC Carrillo International Conference on Advancing the Science of Cancer in Latinos (Feb 26-28, 2020, San Antonio, TX), poster

Successful implementation of a novel trial design in a palliative care population

K Arnold;G Anderson;J Deneve;R Topacio;R Krouse Society for Clinical Trials (virtual meeting September 1, 2020 - April 30, 2021), poster

2015

Prospective comparative effectiveness trial for malignant bowel obstruction: SWOG S1316

RS Krouse American College of Surgeons Bulletin Dec;100(12):49-50

PMid: PMID26749971

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase